For adults only.
As with any hypoglycemic agent, dosages must be tailored to each particular case.
In case of loss of glycemic control, a short period of drug administration may be sufficient, a patient normally balanced by the regime.
- Subject under 65 years:
- Initial dose: the recommended starting dose is one tablet daily, administered with breakfast.
- Bearings: Dosage adjustments are usually in increments of 1/2 tablet according to the glycemic response. At least several days are required between each dose level.Maintenance Treatment: The usual dose is two tablets per day, once daily for breakfast.
Elderly over 65 years:
Starting treatment with 1/2 tablet once a day.
This dose may be gradually increased until adequate glycemic control over the patient, respecting the minimum levels of seven days and under close monitoring blood glucose.
Other patients at risk:
Patient malnourished or have marked impairment of general condition, or whose calorie intake is irregular and in patients with renal or hepatic impairment, treatment should be initiated at the lowest dose and dosage levels should be strictly adhered to avoid hypoglycemic reactions (see Warnings and Precautions).
Patients receiving other oral hypoglycemic agents:
As with any sulfonylurea, this drug can take over a diabetes treatment without a transition period. When passing a sulfonylurea in longer half-life (such as chlorpropamide) to this drug, patients will be closely monitored (for weeks) to avoid hypoglycemia, due to the possibility of overlapping therapeutic effects.
Glucidoral its appearance and shape
White scored tablet.
Glucidoral How it Works
Sulfonylurea oral antidiabetic
(A: alimentary tract and metabolism).
Carbutamide seems to lower blood glucose acutely by stimulating the release of insulin from the pancreas, this effect being dependent upon the presence of active beta cells in pancreatic islets.
Stimulation of insulin secretion by carbutamide in response to a meal is of major importance. The administration of carbutamide diabetic causes an increase in the postprandial insulin response.
The responses of postprandial insulin secretion and C-peptide continue to be increased at least six months after treatment.
Notice: Want to know when we update our site? Enter your email address below and be notified by mail every time we update our site